A full breakdown of ICICI Lombard's Q4 FY26 results — premiums, claims, expenses, and why retail health is the standout story.
When a general insurance company reports its quarterly results, the numbers can look dense at first glance. But once you break them down, they tell a fairly straightforward story about premiums, claims, and how the business is running.
That's exactly what the Q4 FY26 results of ICICI Lombard General Insurance show: a mix of strong premium growth, a rise in claims, and steady profitability.
Let's walk through it step by step.
The company reported a profit of ₹547 crore, which is 7.3% higher than last year's ₹510 crore for the same quarter.
Net Premium Earned (NPE), or the revenue insurers actually recognise from policies, grew by 10.8% to ₹5,791 crore. It's worth noting that the company's Gross Direct Premium Income (GDPI), its headline growth metric, grew even faster: 18.2% in Q4 FY26 versus industry growth of 10.9%.
Here's a quick snapshot of the key numbers:
| Metric | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Net Premium Earned (NPE) | ₹5,790.53 crore | ₹5,226 crore |
| Total Income | ₹6,618.76 crore | ₹5,481.03 crore |
| Total Expense | ₹6,072.91 crore | ₹5,435.25 crore |
| Profit After Tax | ₹546.56 crore | ₹509.59 crore |
Source: NSE
Overall, profit, premiums, and total income all grew year-on-year — total income was up roughly 20.7%, reflecting higher underwriting activity across the quarter.
Insurance is, at its core, about premiums. And this quarter, those numbers moved up across the board.
| Metric | Q4 FY26 (₹ lakh) | Q4 FY25 (₹ lakh) |
|---|---|---|
| Gross Premiums Written | 8,07,370 | 7,43,298 |
| Net Premium Written | 6,48,744 | 5,96,348 |
| Net Premium Earned | 5,79,053 | 5,22,558 |
| Income from Investments | 79,668 | 90,901 |
| Other Income | 3,155 | 1,584 |
Source: NSE
Both gross and net premiums increased, indicating higher policy issuance and stronger revenue recognition during the quarter. The retail health segment was a standout driver, with growth fuelled by GST reforms on health insurance premiums that improved product affordability and broadened the base of new customers.
Meanwhile, investment income came in lower than last year, this is typically influenced by market-linked factors and can vary across periods.
Now, this is the other side of the story.
| Expense Head | Q4 FY26 (₹ lakh) | Q4 FY25 (₹ lakh) |
|---|---|---|
| Commissions & Brokerage | 1,18,757 | 1,02,642 |
| Employee Expenses | 42,456 | 39,332 |
| Other Operating Expenses | 36,098 | 27,234 |
| Claims Paid | 3,92,474 | 3,38,552 |
| Total Expenses | 6,07,291 | 5,43,525 |
The biggest number here is claims paid, which rose year-on-year. Total expenses also increased by around 11.7%, broadly in line with premium growth — this is a normal pattern when a business is writing more policies. Commissions and employee expenses also moved up alongside the growth in premiums.
Breaking the numbers down further gives a clearer picture of where the business is coming from.
| Segment | Q4 FY26 (₹ lakh) | Q4 FY25 (₹ lakh) |
|---|---|---|
| Fire | 18,182 | 16,325 |
| Marine | 16,096 | 14,985 |
| Health – Retail | 59,447 | 38,193 |
| Health – Group/Corporate | 1,71,420 | 1,55,965 |
| Health – Government | 313 | 140 |
Retail health was the clear growth leader, up over 55% year-on-year, driven by GST reforms and a wider customer base. Group health also grew steadily.
Along with the results, the Board proposed a final dividend of ₹7 per share for FY26, subject to shareholder approval at the AGM.
| Particulars | Value |
|---|---|
| Final Dividend per Share | ₹7 |
| Face Value | ₹10 |
| Dividend as % of Face Value | 70% |
| Approval Status | Subject to AGM approval |
For context, the total FY26 dividend, including interim, is ₹13.50 per share, up from ₹12.50 in FY25.
If you step back and look at the full picture, a few things become clear:
There's no sharp spike or sudden shift in any one area — the performance reflects a continuation of ongoing business trends, with retail health as a notable high-growth area.
Disclaimer: This article was researched and drafted with the assistance of AI tools, based on publicly available financial filings — specifically ICICI Lombard's Q4 FY26 investor presentation and NSE financial statements. All numbers have been verified against source documents. This article is for informational purposes only and does not constitute financial advice. Please consult a SEBI-registered advisor before making investment decisions.